FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Juvantia Pharma

Santhera Reports Closing of Juvantia Acquisition and Final Upfront Payment from Partner Biovail

05-Oct-2009 - Santhera Pharmaceuticals announced the final closing of the acquisition of Oy Juvantia Pharma Ltd of Turku, Finland. Santhera issued 105,973 previously reserved shares from its authorized share capital to Juvantia investors, as announced when exercising its option to acquire Juvantia on August ...

dyskinesia Finland levodopa induced dyskinesia +2

Santhera Acquires Juvantia and Secures All Rights to JP-1730/Fipamezole

17-Aug-2009 - Santhera Pharmaceuticals announced that it exercised its option to acquire Oy Juvantia Pharma Ltd of Turku, Finland, the owner of JP-1730/fipamezole. Santhera will issue up to 105,973 previously reserved shares from its authorized capital to Juvantia investors subject to certain conditions. ...

dyskinesia Finland Parkinson's disease +1

Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease

12-Nov-2007 - Santhera Pharmaceuticals and Juvantia Pharma Ltd announced that the first patient has been enrolled into a Phase IIb clinical trial to evaluate JP-1730 (INN: fipamezole) for the treatment of Dyskinesia in Parkinson's Disease (DPD). The study is designed to confirm the dual efficacy of the ...

clinical trials dyskinesia levodopa induced dyskinesia +4

Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson's Disease

07-Sep-2006 - Santhera Pharmaceuticals and Juvantia Pharma announced that they have entered into a strategic collaboration to advance the development of Juvantia's fipamezole (JP-1730) for the treatment of Dyskinesia in Parkinson's Disease (DPD) patients. A Phase IIa clinical trial in the US has already shown ...

clinical trials dyskinesia Parkinson's disease +2